In 2024, the market size of autoimmune drugs may reach nearly 50 billion yuan

 Autoimmune diseases are diseases in which the immune system mounts an immune response against the body's own normal components and damages the organs and tissues
.
At present, there are about 100 different types of autoimmune diseases, the common ones are rheumatoid arthritis, ankylosing spondylitis, psoriasis and so on
.
With the improvement of residents' disposable income and the advancement of medical technology, the market demand for autoimmune disease treatment drugs is showing a rapid growth trend in recent years
.
A market research report shows that in 2019, the sales of autoimmune disease drugs in China has grown to 15.
8 billion yuan
.
It is estimated that by 2024, sales of autoimmune disease drugs are expected to rise by 46.
2 billion yuan
.
Notably, as the market continues to expand
.
At present, more and more pharmaceutical companies have begun to increase their layout in this field
.
It is understood that the current global pharmaceutical giants are almost all deployed in the field of autoimmunity.
The prominent ones are Pfizer, Novartis, Johnson & Johnson, and AbbVie.
There are more than 18 products under development or on the market in the pipelines of the above companies
.
On the whole, the main targets of most drugs have been tumor necrosis factor (TNF) and interleukin, and the development targets of small molecule compounds are mostly tyrosine kinase inhibitors, such as Janus kinase, (JAK) and Bruton tyrosine.
Kinase (BTK)
etc.
Of course, in the face of the huge market, domestic enterprises will not miss it
.
On February 23, Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co.
, Ltd.
(“Zhongmei Huadong”) and Kiniksa Pharmaceuticals (UK), Ltd.
(hereinafter referred to as Kiniksa) signed an exclusive product license agreement.

.
The announcement shows that Sino-US Huadong has obtained the exclusive licenses of two autoimmune global innovative products Arcalyst and Mavrilimumab from Kiniksa in 24 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia, New Zealand and India, including development, registration and commercial Equity
.
MidAmerican East will pay Kiniksa an upfront payment of $22 million, development, registration and sales milestone payments of up to $640 million, as well as tiered double-digit royalties on net sales
.
In addition to Huadong Medicine, many domestic companies have increased their layout in the field of self-freedom in recent years, and Sunshine Guojian has performed very well
.
Incomplete statistics show that as of November 2021, in its R&D pipeline, in addition to the marketed TNF-α inhibitor Yisaipu, there are 5 self-immune drugs under development, 3 of which have completed clinical phase I trials.
, 1 is in Phase I clinical trials, and 1 is in the pre-IND stage
.
Among them, SSGJ-608 is an inhibitor targeting IL-17A, and the declared indication is moderate to severe plaque psoriasis
.
Data show that the incidence of psoriasis in China is about 0.
47%, with nearly 6.
5 million patients, of which 57.
3% are moderate to severe patients
.
The industry predicts that if the drug can be successfully launched, the market space will be very broad
.
In general, with the improvement of autoimmune disease diagnosis in the future, the large number of autoimmune disease patients and the promotion of policies, China's autoimmune disease drug market will continue to maintain rapid growth
.
In this context, pharmaceutical companies and capital will continue to enter the market to promote the accelerated approval and marketing of domestic autoimmune disease drugs, bringing more new drug options to relevant domestic patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.